Carregant...
New Strategies for Treatment of ALK Rearranged Non-Small Cell Lung Cancers
The identification of oncogenic alterations in subsets of non-small cell lung cancers (NSCLC) is transforming clinical care. Genomic rearrangements in the anaplastic lymphoma kinase (ALK) are detected in 3 to 7% of NSCLC patients. The ALK tyrosine kinase inhibitor crizotinib has demonstrated clinica...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3477548/ https://ncbi.nlm.nih.gov/pubmed/22010214 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1404 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|